Skip to main content
SpringerLink
Log in

18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

To investigate the usefulness of 18F-FP-CIT PET for assessing the severity of Parkinson’s disease (PD) at various clinical stages, 41 patients with PD were divided into early (Hoehn&Yahr I-II, n = 23) and advanced (Hoehn&Yahr III-IV, n = 18) subgroups. 18F-FP-CIT PET was performed in these patients and 12 normal subjects. 18F-FP-CIT uptake in striatal subregions and its correlation with UPDRS were first evaluated by ROI analysis, and between-group differences were also analyzed by Statistical Parametric Mapping (SPM). Our results showed that striatal 18F-FP-CIT binding were significantly reduced to 70.9% (caudate), 46.8% (anterior putamen) and 24.0% (posterior putamen) in early PD compared with that of the control, and to 52.0%, 34.5% and 16.5% correspondingly in advanced PD, respectively. There was significant negative correlation between total motor UPDRS score of all parkinsonian patients and 18F-FP-CIT uptake in caudate nucleus (r = −0.53, p < 0.001), anterior putamen (r = −0.53, p < 0.001) and posterior putamen (r = −0.61, p < 0.001). SPM comparison of 18F-FP-CIT uptake between early or advanced PD and the control group showed significant decline in striatum, predominantly localized on the contralateral side and in the dorsal-posterior putamen. These results indicate that 18F-FP-CIT PET can serve as a suitable biomarker to represent the severity of PD in early and advanced stages.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Booij J, Habraken JB, Bergmans P, et al. (1998) Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 39:1879–1884

    PubMed  CAS  Google Scholar 

  2. Ribeiro MJ, Vidailhet M, Loc’h C, et al. (2002) Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 59:580–586

    Article  PubMed  Google Scholar 

  3. Rinne JO, Ruottinen H, Bergman J, et al. (1999) Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:737–741

    PubMed  CAS  Google Scholar 

  4. Morrish PK, Rakshi JS, Bailey DL, et al. (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64:314–319

    PubMed  CAS  Google Scholar 

  5. Kazumata K, Dhawan V, Chaly T, et al. (1998) Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 39:1521–1530

    PubMed  CAS  Google Scholar 

  6. Kung HF, Kim HJ, Kung MP, et al. (1996) Imaging of dopamine transporters in humans with technetium-99 m TRODAT-1. Eur J Nucl Med 23:1527–1530

    Article  PubMed  CAS  Google Scholar 

  7. Huang WS, Chiang YH, Lin JC, et al. (2003) Crossover study of (99 m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson’s disease patients. J Nucl Med 44:999–1005

    PubMed  Google Scholar 

  8. Rinne OJ, Nurmi E, Ruottinen HM, et al. (2001) [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson’s disease. Synapse 40:193–200

    Article  PubMed  CAS  Google Scholar 

  9. Tedroff J, Ekesbo A, Rydin E, et al. (1999) Regulation of dopaminergic activity in early Parkinson’s disease. Ann Neurol 46:359–365

    Article  PubMed  CAS  Google Scholar 

  10. Ishikawa T, Dhawan V, Kazumata K, et al. (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 37:1760–1765

    PubMed  CAS  Google Scholar 

  11. Wang GJ, Volkow ND, Fowler JS, et al. (1995) Comparison of two pet radioligands for imaging extrastriatal dopamine transporters in human brain. Life Sci 57:L187-L191

    Google Scholar 

  12. Guttman M, Burkholder J, Kish SJ, et al. (1997) [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson’s disease: implications for the symptomatic threshold. Neurology 48:1578–1583

    PubMed  CAS  Google Scholar 

  13. Ilgin N, Zubieta J, Reich SG, et al. (1999) PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson’s disease. Neurology 52:1221–1226

    PubMed  CAS  Google Scholar 

  14. Laakso A, Bergman J, Haaparanta M, et al. (1998) [18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse 28:244–250

    Article  PubMed  CAS  Google Scholar 

  15. Robeson W, Dhawan V, Belakhlef A, et al. (2003) Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects. J Nucl Med 44:961–966

    PubMed  CAS  Google Scholar 

  16. Ma Y, Dhawan V, Mentis M, et al. (2002) Parametric mapping of [18F]FPCIT binding in early stage Parkinson’s disease: a PET study. Synapse 45:125–133

    Article  PubMed  CAS  Google Scholar 

  17. Eshuis SA, Maguire RP, Leenders KL, et al. (2006) Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging 33:200–209

    Article  PubMed  CAS  Google Scholar 

  18. Nurmi E, Ruottinen HM, Kaasinen V, et al. (2000) Progression in Parkinson’s disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47:804–808

    Article  PubMed  CAS  Google Scholar 

  19. Nurmi E, Bergman J, Eskola O, et al. (2003) Progression of dopaminergic hypofunction in striatal subregions in Parkinson’s disease using [18F]CFT PET. Synapse 48:109–115

    Article  PubMed  CAS  Google Scholar 

  20. Marek K, Innis R, van Dyck C, et al. (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 57:2089–2094

    PubMed  CAS  Google Scholar 

  21. Benamer HT, Patterson J, Wyper DJ, et al. (2000) Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692–698

    Article  PubMed  CAS  Google Scholar 

  22. Hughes AJ, Daniel SE, Kilford L, et al. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

    Article  PubMed  CAS  Google Scholar 

  23. Pellizari CA, Chen GTY, Spelbring DR (1989) Accurate three-dimensional registration of CT, PET and/or MR images of the brain. J Comput Assist Tomogr 13:20–26

    Article  Google Scholar 

  24. Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain. Thieme, Stuttgart

    Google Scholar 

  25. Ma Y, Dhawan V, Spetsieris P, et al. (2002) Comparison of Mapping Parameters in 18F-FPCIT imaging of early stage Parkinson’s disease. In: Michio Senda, Yuichi Kimura, Peter Herscovitch (eds) Brain imaging using PET. Academic Press, San Diego, pp 277–283

  26. Carbon M, Ma Y, Barnes A, et al. (2004) Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage 21:1497–1507

    Article  PubMed  Google Scholar 

  27. Asenbaum S, Brucke T, Pirker W, et al. (1997) Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson’s disease. J Nucl Med 38:1–6

    PubMed  CAS  Google Scholar 

  28. Seibyl JP, Marek KL, Quinlan D, et al. (1995) Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38:589–598

    Article  PubMed  CAS  Google Scholar 

  29. Antonini A, Moresco RM, Gobbo C, et al. (2001) The status of dopamine nerve terminals in Parkinson’s disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol Sci 22:47–48

    Article  PubMed  CAS  Google Scholar 

  30. Morrish PK (2003) How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease? Mov Disord 18(Suppl 7):S63-S70

    Article  PubMed  Google Scholar 

  31. Ravina B, Eidelberg D, Ahlskog JE (2005) The role of radiotracer imaging in Parkinson disease. Neurology 64:208–215

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

We thank Dr. Yilong Ma at North Shore University Hospital in New York for his critical review of this manuscript and for gracefully providing a 3D stereotactic PET brain template for 18F-FP-CIT binding. We also gratefully acknowledge the financial supports from China’s National Key Technologies R&D Program in the 10th five-year plan (2001BA702B02) and Key Research Grants of Health Department in Jiangsu Province (H2008).

Author information

Authors and Affiliations

  1. Dept. of Neurology, Huashan Hospital affiliated to Fudan University, Shanghai, China

    Jian Wang, Yu-Ping Jiang, Li-Qin Yang, Zheng-Tong Ding & Jian-jun Wu

  2. PET Center, Huashan Hospital affiliated to Fudan University, Shanghai, China

    Cuan-Tao Zuo & Yi-Hui Guan

  3. National Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China

    Zheng-Ping Chen & Jing-De Xiang

  4. Dept. of Neurology, Third People’s Hospital, Huzhou, Zhejiang, China

    Hui-Lin Su

  5. Dept. of Neurology, Huashan Hospital affiliated to Fudan University, 12 Wulumuqi Zhong Road, Shanghai (ShangHai), 200040, China

    Jian Wang

Authors
  1. Jian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cuan-Tao Zuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-Ping Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi-Hui Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zheng-Ping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing-De Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li-Qin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zheng-Tong Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jian-jun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hui-Lin Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Wang.

Additional information

Received in revised form: 11 June 2006

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, J., Zuo, CT., Jiang, YP. et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages. J Neurol 254, 185–190 (2007). https://doi.org/10.1007/s00415-006-0322-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-006-0322-9

Keywords

Search

Navigation